Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children.
The paper discusses the experience accumulated so far in the field of application of ursodeoxycholic acid (UDCA) in selected disorders of the liver and biliary ducts in the developmental age population. In the aforementioned diseases, chronic administration of UDCA is safe, reduces the clinical symptoms, improves the biochemical parameters, and even the histopathologic picture of the affected organ. Such a therapy should be instituted in order to improve the quality of life, reduce the incidence of complications and postpone the transplantation of the liver till the time the child is older.
Lebensztejn
D M
DM
3rd Department of Pediatric Diseases, Medical University of Białystok, ul. Waszyngtona 17, 15-274 Białystok, Poland.
D016738:Alagille Syndrome / Q000188:drug therapy; D001649:Bile Duct Diseases / Q000188:drug therapy*; D002648:Child; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D002780:Cholestasis, Intrahepatic / Q000188:drug therapy / Q000235:genetics; D003550:Cystic Fibrosis / Q000188:drug therapy; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy*; D010289:Parenteral Nutrition, Total / Q000009:adverse effects; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*
D002756:Cholagogues and Choleretics; D014580:Ursodeoxycholic Acid